Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study of real-world outcomes in advanced renal cell carcinoma patients treated with either axitinib/pembrolizumab (A/P) or ipilimumab/nivolumab (I/N)

Next Previous
Trial Profile

A retrospective study of real-world outcomes in advanced renal cell carcinoma patients treated with either axitinib/pembrolizumab (A/P) or ipilimumab/nivolumab (I/N)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 08 Feb 2023 Results comparing real-world outcomes in patients treated with axitinib/pembrolizumab (axi/pembro) or ipilimumab/nivolumab, published in the Oncologist
  • 13 Jul 2021 New trial record
  • 08 Jun 2021 Primary endpoint (real-world progression free survival (rwPFS)) has not been met, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top